{
  "docId": "019dd923-622c-750b-8b97-e9d223c0ba42",
  "docSlug": "88a4417a0cf1",
  "documentTitle": "Apellis Pharmaceuticals (APLS)",
  "authorId": "52_Citron_Research",
  "authorName": "Citron Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-11-06 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77295077,
  "pageNumber": 7,
  "pageCount": 13,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "Includes a direct quote from an earnings call and a chart from a Jefferies analyst report.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/7",
  "deckHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Citron has reason to believe that CEO Cedric Francois is not being honest with Wall St. about the report cases of vasculitis.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcd8-4ff0662fd290",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.734,
        "x": 0.133,
        "y": 0.309
      },
      "kind": "chart",
      "text": "Beovu Units Volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3832c0f7-6ad8-4697-a1dc-6cfaf739cd9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.764,
        "x": 0.118,
        "y": 0.148
      },
      "kind": "paragraph",
      "text": "Where there is smoke there must be fire and the metaphorical smoke in hallways of the AAO conference is obvious. The clinical trials are not matching the real-world profiles in safety and efficacy and the FDA should at a minimum put a warning label on Syfovre.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9fb2f0f-d40f-4f42-afa2-463f9c862b39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.764,
        "x": 0.118,
        "y": 0.84
      },
      "kind": "quote",
      "text": "So we're going to stop talking about individual cases because frankly that's not an effort that we think is fruitful. To put this in perspective, the last case of a patient with geographic atrophy that was reported to us with vasculitis is already from September first, right.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "450ddcda-f83a-45fd-bc95-bbe978d2add0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "So we're going to stop talking about individual cases because frankly that's not an effort that we think is fruitful. To put this in perspective, the last case of a patient with geographic atrophy that was reported to us with vasculitis is already from September first, right. — Cedric Francois",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcd8-52e37b68d24c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.55,
        "x": 0.118,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "https://seekingalpha.com/article/4645993-apellis-pharmaceuticals-inc-apls-q3-2023-earnings-call-transcript",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86874529-71a8-4c46-8f9f-c3d8bd548990",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.315,
        "x": 0.118,
        "y": 0.108
      },
      "kind": "title",
      "text": "What happens next to Syfovre?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f3da786-0fa9-4752-a623-22bda0e7a2f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.185,
        "x": 0.118,
        "y": 0.698
      },
      "kind": "title",
      "text": "Securities Fraud?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3df2fbad-4285-424e-8e6e-86f102c2e27b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "9ccf65e3-78f1-4703-8507-c6cb3a8ac444",
      "evidence": "The slide explicitly questions 'Securities Fraud?' and attempts to expose a contradiction between CEO statements and reported safety data.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [
    {
      "to": 8,
      "from": 6,
      "beatId": "ad97bdfc-9557-49c8-b876-02597086cd90",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "Citron Research presents various critiques and data to challenge Apellis' claims.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac",
      "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.",
      "position": 1,
      "objective": "What are the consequences of not taking action against Syfovre's safety concerns?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}